N/A N=15 Randomized Treatment

Effect of Walking on Brain Fuel Consumption in Mild Alzheimer's Disease

Alzheimer's Disease

Bottom Line

View on ClinicalTrials.gov: NCT02708485 ↗

Enrolled (actual)

Serious AEs

—

Results posted

Oct 2018

Primary outcome: Primary: Brain Glucose Consumption — 27.9; 28.1 umol/100 g/min

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Physical exercise (Other)
Age: Adult, Older Adult · 40+ yrs
Sex: All
Sponsor: Université de Sherbrooke
Primary completion: Jul 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Brain Glucose Consumption	27.9; 28.1	—
PRIMARY Brain Acetoacetate Consumption	0.24; 0.64	—

Summary

The aim of this study is to evaluate the effect of a 3-month walking program on brain energy metabolism in patient with mild Alzheimer's disease (AD). Two groups of sedentary patients with mild AD are followed and compared over a 3-month period of time: Control (non-active) and walking (from 15 to 45 minutes of exercise on a treadmill, 3 times a week for 12 weeks) groups. All the participants are evaluated on their cognition, brain volumes (MRI) and brain fuel consumption (PET scan with 18-FDG and 11C-AcAc) at the beginning and at the end of the study.

Eligibility Criteria

Inclusion Criteria

Diagnosis of mild Alzheimer's disease (NINCDS-ADRDA criteria)
Taking cholinesterase inhibitors
Sedentary
Ability to do physical exercise

Exclusion Criteria

Parkinson disease
Down syndrome
Epilepsy or concussion
Drug or alcohol abuse
Past psychiatric history
Vitamin B12 Deficiency
Uncontrolled diabetes or thyroid function

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02708485). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.